

# Semaglutide Treatment for Hyperglycaemia After Renal Transplantation

NCT05702931

---

Status	RECRUITING
Phase	Phase 4
Sponsor	Rigshospitalet, Denmark
Enrollment	104 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Written informed consent obtained before any trial-related procedures are performed
- Male or female; age: 18-80 years
- Diagnosis of post-transplant hyperglycaemia 10 to 40 days after transplantation: Fasting plasma glucose  $\geq$  7.0 mmol/L or an oral glucose tolerance test with at plasma glucose  $\geq$  11.1 mmol/L or Pre-transplant type 2 diabetes: Receiving glucose-lowering treatment prior to kidney transplantation
- An eGFR  $\geq$  15 ml/min/1.73 m<sup>2</sup> 10 to 40 days after renal transplantation
- Subject must be willing and able to comply with trial protocol

### Exclusion (18)

- Type 1 diabetes
  - Dialysis
  - High risk immunological transplantation (not including ABO-incompatible or re-transplantation)
  - Early graft rejection (all rejections verified by biopsy, except borderline rejections. Study initiations can begin 5 days after last dose of rejection treatment with methylprednisolone)
  - Chronic pancreatitis/previous acute pancreatitis
- ... and 13 more (see full listing online)

## Locations (1 total)

---

Department og Nephrology and Endocrinology, Rigshospitalet, Copenhagen, Denmark